Clinical trial
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
ClinicalTrials.gov ID: NCT05359068
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Information provided by: Shanghai Pharmaceuticals Holding Co., Ltd (Responsible Party)
Last Update Posted: 2023-09-26
Brief Summary:
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
Official Title:
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension
Intervention / Treatment:
- Drug: SPH3127 tablet
- Drug: SPH3127 tablet
- Drug: SPH3127 tablet
- Drug: Valsartan
- Drug: SPH3127 tablet
- Drug: Valsartan
| Category | Value |
|---|---|
| Study Start (Actual) | 2021-06-10 |
| Primary Completion (Estimated) | 2023-10-31 |
| Study Completion (Estimated) | 2024-04-30 |
| Enrollment (Estimated) | 900 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
SPH3127-301 |